Ultimovacs ASA (OSL:ULTI) Total Long-Term Liabilities : kr13.54 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Ultimovacs ASA's Total Long-Term Liabilities for the quarter that ended in Dec. 2023 was kr13.54 Mil.

Ultimovacs ASA Total Long-Term Liabilities Historical Data

The historical data trend for Ultimovacs ASA's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Total Long-Term Liabilities Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Liabilities

Get a 7-Day Free Trial

13.15

13.87

11.49

14.41

13.54

Ultimovacs ASA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Long-Term Liabilities	Get a 7-Day Free Trial															14.41	14.63	14.12	13.24	13.54

Ultimovacs ASA Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Ultimovacs ASA Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.